1. Volume 387, Issue 10021, Pages 866-873 (February 2016)
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 
Prof John F Forbes, MD, Ivana Sestak, PhD, Prof Anthony Howell, MD, Bernardo Bonanni, MD, Prof Nigel Bundred, MD, Christelle Levy, MD, Prof Gunter von Minckwitz, MD, Wolfgang Eiermann, MD, Prof Patrick Neven, MD, Prof Michael Stierer, MD, Chris Holcombe, MD, Prof Robert E Coleman, MD, Prof Louise Jones, PhD, Prof Ian Ellis, MD, Prof Jack Cuzick, PhD 
The Lancet 
Volume 387, Issue 10021, Pages (February 2016)
DOI: /S (15)
Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
ER=oestrogen receptor. DCIS=ductal carcinoma in situ.
The Lancet  , DOI: ( /S (15) )
Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Recurrence for all breast cancer according to treatment allocation
The Lancet  , DOI: ( /S (15) )
Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Subgroup analyses for invasive breast cancer by cancer characteristics
Numbers do not add to totals because of missing values. The dotted line shows no effect point, and the bold line shows overall treatment effect point. ER=oestrogen receptor.
The Lancet  , DOI: ( /S (15) )
Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions